Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

The high complete remission rate with first-line combined fludarabine, cyclophosphamide, and rituximab (FCR) begs the question of the value of minimal residual disease (MRD)–negative status as a treatment end point. We report on 237 patients with chronic lymphocytic leukemia who received first-line...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Strati, Paolo, Keating, Michael J., O'Brien, Susan M., Burger, Jan, Ferrajoli, Alessandra, Jain, Nitin, Tambaro, Francesco Paolo, Estrov, Zeev, Jorgensen, Jeffrey, Challagundla, Pramoda, Faderl, Stefan H., Wierda, William G.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4067501/
https://ncbi.nlm.nih.gov/pubmed/24705492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-11-538116
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados